Hims & Hers Shares Rally 19% in Two Days on FDA Peptide Review Plan
Shares of Hims & Hers rallied 6% after a prior 13% surge when Health Secretary Robert F. Kennedy Jr. announced an FDA July meeting to reclassify seven peptides for advisory review. The development supports the telehealth provider’s California peptide plant acquired last year to scale weight-loss and muscle-recovery treatments.
1. July Meeting to Reassess Peptides
The FDA has moved seven peptides from Category 2 into review by the Pharmacy Compounding Advisory Committee starting in July, allowing independent experts to evaluate clinical and safety data and potentially restore regulated compounding access.
2. Shares Surge on Regulatory Optimism
Hims & Hers stock rose 13% in a single day and added 6% the following session, reflecting investor optimism over looser peptide restrictions despite a 23% year-to-date decline.
3. Peptide Manufacturing Facility Boost
The company’s California peptide plant, acquired last year, positions it to capitalize on expanded compounding rights across treatments including GLP-1 weight-loss and muscle recovery.